DCPH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 29, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on September 20, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on DCPH as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
DCPH moved below its 50-day moving average on September 20, 2023 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DCPH crossed bearishly below the 50-day moving average on September 13, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for DCPH entered a downward trend on October 03, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DCPH advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
DCPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.459) is normal, around the industry mean (86.487). P/E Ratio (0.000) is within average values for comparable stocks, (58.641). DCPH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.372). DCPH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (7.289) is also within normal values, averaging (62.270).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DCPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DCPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel drug candidates to improve the lives of cancer patients
|MFs / NAME||Price $||Chg $||Chg %|
|Columbia Large Cap Value Inst|
|Intrepid Small Cap Investor|
|Manning & Napier Real Estate W|
|Nuveen Winslow Large-Cap Growth ESG I|
|Fidelity® Growth Company K6|
A.I.dvisor indicates that over the last year, DCPH has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DCPH jumps, then ACET could also see price increases.